Early Detection of Hepatocellular Carcinoma on top of Liver Cirrhosis: The Fas Receptor and Ligand System

Olfat Hammam 1, Manal Zahran 2, Ola Mahmoud 2, Sohair Aly 3, Karim Hosny 4, Amira Helmy 5, Amgad Anas 6

1 Department of Pathology, Theodor Bilharz Research Institute, Cairo, Egypt
2 Department of Hematology, Theodor Bilharz Research Institute, Cairo, Egypt
3 Advanc Dental/Medical institute IPPT,USM, Malysia & Medicinial Chemistry Department of NRC.Cairo, Egypt
4 Department of Surgery. Faculty of Medicine (Kasr El Aini Hospital), Cairo University, Egypt
5 Department of Electron Microscop (Hematology), Theodor Bilharz Research Institute, Cairo, Egypt
6 Department of Hepatology & Gasteroenterology, Theodor Bilharz Research Institute, Cairo, Egypt.

Address for correspondence : Theodor Bilharz Research Institute, Cairo, Egypt

Abstract

Background:
Hepatocyte aberrations, accumulation of chromosomal damage and possibly initiation of hepatic carcinogenesis is thought to be caused by the continued viral replication and the persistent attempt by a less than optimal immune response to eliminate hepatitis C virus (HCV) infected cells. The identification of the “death factors” including Fas and its Ligand (Fas-L) as a major regulator of both apoptosis and immune function has provided insight into an attractive mechanism of tumor escape from immune clearance.

Aim: To assess the hepatic expression of Fas/Fas-L, the Fas receptor (Fas-R) expression on lymphocyte, and serum soluble Fas (sFas) in an attempt to analyze the role of Fas receptor/ligand system in the multistep process of fibrosis/carcinogenesis and the possible use of the serum marker as possible candidate biomarkers for an early detection of hepatocellular carcinoma (HCC).

Material and Method:
The current study included 100 samples from cases at Theodor Bilharz Research Institute and Kasr Al Aini Hospital in Egypt. There were 90 cases of chronic hepatitis C (CHC) infection (and negative hepatitis B virus infection). There were 30 cases without liver cirrhosis, 30 cases with liver cirrhosis and 30 cases with HCC. 10 liver biopsies were taken from healthy livers as normal controls. Histopathologic study and immunohistochemistry for detection of hepatic Fas and Fas-L expression were determined for all cases. Electron microscopy (EM) and immunoelectron microscopy (IEM) examination for detection of Fas-R expression on lymphocytes were also done. sFas, liver function tests, serologic markers for viral hepatitis, and serum alpha-fetoprotein level (alpha-FP) were done.
Results:
The sFas in both HCC and CHC with cirrhosis patients were significantly higher than those of normal controls and CHC without cirrhosis (P<0.01), but there was no significant difference between the cirrhosis and HCC patients. Positive hepatic expression of both Fas and Fas-L were significantly increased in the diseased groups (p<0. 01) compared to the control specimens. A progressive Fas and FasL increase from CHC without cirrhosis to CHC with cirrhosis followed by a decline from the latter to HCC. Apoptotic Fas and Fas-L proteins expression was significantly increased with the necroinflammatory activity and the advancement of fibrosis. There was a non-significant negative correlation between sFas and hepatic Fas. In addition a significant over expression of Fas-R on separated lymphocytes was associated with a higher frequency of apoptotic cell death as detected by EM examination.

Conclusion:
The Fas receptor/ligand system was significantly involved in the process of liver cirrhosis converting into HCC. Down-regulation of Fas expression, up-regulation of Fas-L expression in hepatocytes and elevation of serum sFas level were important in tumor evasion from immune surveillance and in hepatic carcinogenesis.

Key Words: hepatocellular carcinoma, cirrhosis, Fas, Fas ligand, hepatitis C

Abbreviations:
Hepatitis C virus (HCV), hepatocellular carcinoma (HCC), chronic hepatitis C (CHC), Fas Ligand (FasL), Fas receptor (FasR), serum soluble Fas (sFas), alpha-fetoprotein level (alpha-FP).

Introduction

Hepatitis C Virus (HCV) is recognized as a major threat to global public health. An estimated 170 million people worldwide are infected, most of them are chronically infected and at risk for liver cirrhosis and hepatocellular carcinoma (HCC) (Coulon et al., 2010). Immunophenotyping of intrahepatic infiltrating inflammatory cells in chronic hepatitis C (CHC) patients showed a predominance of T-lymphocytes cells, with a significant proportion of CD4+ and CD8+ cells, suggesting that the host immune system is involved in liver disease pathogenesis (Onji et al., 1992). The continued viral replication and persistent attempt by a less than optimal immune response to eliminate HCV-infected cells are implicated in hepatocyte aberrations, accumulation of chromosomal damage and possibly initiation of hepatic carcinogenesis (Ahn et al., 2004).
Our immune system, charged with the function of cancer surveillance, has complex and efficient capability to clear genetically altered cells that have undergone malignant transformation. Tumor cells must develop strategies to avoid clearance by the immune system to survive, expand their populations and metastasize (Patel, 1999). The identification of the “death factors” including Fas and its Ligand (Fas-L) as a major regulator of both apoptosis and immune function has provided insight into an attractive mechanism of tumor escape from immune clearance (Nagata, 1997).

Fas and Fas-L are transmembrane proteins of the tumor necrosis factor family of receptors and ligands. Engagement of Fas by Fas-L triggers a cascade of well-characterized intracellular signaling events that culminate in cell death by apoptosis (Nagata and Goldstein, 1995). Fas receptors are widely expressed in normal and diseased tissues. It has been implicated in tumor progression of several cancers (Viard-Leveugle et al., 2003; Bebenek et al., 2008).

Fas-L is expressed mainly in cytotoxic T-lymphocyte (Suda et al., 1993), immune privileged sites (Griffith et al., 1995) and in various tumors where specific cytotoxic T-cell clones are produced (Lee et al., 1998). Fas-L over expression was found to be related to advanced stage in many tumors (Viard-Leveugle et al., 2003; Pryczynicz et al., 2010).

Apoptosis is tightly regulated throughout a variety of mechanisms, one of which is postulated to be the production of sFas which is an antagonistic decay protein similar to Fas, except that it lacks the transmembrane domain. It normally binds to FasL, thus blocking the signaling of the membrane-bound form of Fas. Elaboration of sFas by tumor cells, by alternative mRNA splicing, may contribute to resistance to Fas-mediated apoptosis (Nagao et al., 1999).

Therefore, due to the importance of the Fas system members (Fas, FasL and sFas), this study was designed to assess the hepatic tissue expression of Fas/FasL, Fas receptor (FasR) expression on T-lymphocytes using electron microscope (EM) and immunoelectron microscope (IEM) examination and the circulating serum level of sFas in chronic hepatitis C liver disease, to analyze the role of these factors in the multistep process of fibrosis/carcinogenesis and the possible use of the serum marker as possible candidate biomarkers for an early detection of HCC.

Patients and Methods

This study enrolled 90 chronic HCV patients (54 males and 36 females), age range between 24-66 years with a
mean of 48.32±7.65 admitted to the Hepatology and Gastroenterology Department at Theodor Bilharz Research Institute (TBRI) and Kasr Al Aini Hospital. Liver and tumor specimens were taken by surgery and endoscopy from hepatectomies. They included 30 cases of chronic hepatitis C virus infection without hepatic cirrhosis, 30 cases with hepatic cirrhosis and 30 cases with HCC. Patients with liver disease of other etiology were excluded. The diagnosis of cirrhotic patients was made on the basis of clinical history, clinical examinations, laboratory findings, gastroscopy and ultrasonography. In addition, ten control liver biopsies were taken from age- and sex-matched individuals undergoing laparoscopic cholecystectomy (7 males and 3 females, age range between 31-45 years with a mean of 42.21±4.54). Written informed consent was obtained from all participants and the TBRI local ethical committee approved the study.

**Sampling**

Blood samples of 8 ml were collected into sterile endotoxin-free vacuum blood collection tubes on potassium EDTA. The peripheral blood mononuclear cell (PBMNC) layer was separated using Ficoll Hypaque (Seromid Biochrom, Berlin, Germany) density gradient centrifugation and washed 3 times with Hank's balanced salt solution (HBSS) without Ca2+ and Mg2+ ions (Helmy et al, 2007). These cells were prepared for EM examination using agarose cell block technique in addition to the IEM examination. Another 2 ml of blood were withdrawn into plain tube and centrifuged shortly after clot formation. All samples were stored at −70°C in aliquots and used for analysis of sFas.

Formalin-fixed and paraffin embedded tissues from tumor samples were used for immunohistochemical analysis of Fas and FasL. Liver biopsies are analyzed according to a histological METAVIR (Bedossa and Poynard, 1996) scoring system. Using two separate scores, one for necroinflammatory grade (A for activity) A1: minimal activity, A2: moderate activity, A3: severe activity and another for the stage of fibrosis (F) which scores fibrosis from F0-F4. Starting with a score of F1 with minimal fibrosis and increasing till F4 signifies advanced fibrosis.

**Routine laboratory investigations:**

Complete haemogram using automated haemogram (ACT Differential, Beckman, France). Liver function tests were carried out using commercially available kits. Circulating anti-HCV antibodies were detected using Murex enzyme immunoassay kit (Murex anti-HCV, Version V; Murex Diagnostics; Dartford, England). The presence of HCV-RNA in patients’ sera was detected by real-time polymerase chain reaction (PCR) using the Amplicor test (Roche Diagnostic Systems; Meylan, France).
**Immunohistochemical analysis**

Immunohistochemical reaction was performed using an avidin biotin complex (ABC) immunoperoxidase technique according to Hsu and Raine, 1981 using anti human Fas and FasL on paraffin sections; dewaxed in xylene and hydrated in descending grades of ethanol. Endogenous peroxidase activity was quenched by incubation in 3% hydrogen peroxide in 100% methanol for 20 min. Antigen retrieval was performed by microwaving the sections in citrate buffer (PH 6.0) for 15 min at 700 W. Sections were incubated overnight at 4°C with the anti-human primary antibodies against Fas and Fas Ligand (purchased from Santa Cruz Biotechnology Inc.; Santa Cruz, USA) monoclonal antibody, diluted at 1:100, 1:150 respectively in BPS. Next day, after thorough washing in PBS, the sections were incubated with streptavidin-biotin-peroxidase preformed complex and using a peroxidase/DAB (3, 3'-diaminobenzidine) enzymatic reaction. Staining is completed by 5-10 minutes results in a brown-colored precipitate at the antigen site. The cell nuclei were counterstained with Mayer's hematoxylin. The cover slips were mounted using Dpx.

Positive and negative control slides for each marker were included within each session. As a negative control, liver tissue section was processed in the above mentioned sequences but the omission of the primary antibody and PBS was replaced.

The scoring of Fas and FasL in liver tissue was based on intensity and extensiveness (by percentage population) of the positively stained cells. Both parameters were scored on a scale of 0-3 as follows:

(1) **Intensity:**
- 0 = negative staining (-)
- 1 = weakly positive staining (+)
- 2 = moderately positive staining (++)
- 3 = strongly positive staining (+++)

(Chen et al, 2003)

(2) **Range:**
- 0 = negative
- 1 = positive staining in < 10% of cells
- 2 = staining in 10%-50%
- 3 = staining in > 50% of cells

(Itoi et al, 2004)

Liver sections were examined by Zeiss light microscopy at power X400, X200 and X100 for both markers; the number of positively stained cells with the highest expression was semi-quantitatively recorded within ten successive fields were counted / section and the final value represents the mean. Zero percentage was given to unstained sections.
Early Detection of Hepatocellular Carcinoma on top of Liver Cirrhosis…. 

**Measurements of Serum Soluble Fas (sFas) Levels**

Serum Fas levels were assayed using a sandwich enzyme-linked immune-sorbent assay kit (Biosource International, Camarillo, California, USA) according to the manufacturer’s instructions. Briefly, diluted serum samples and standard were added in duplicate to 96-well microtitre plates coated with Fas antibody and another biotinylated Fas antibody was added. The plate was incubated at room temperature for 1 h, followed by incubation with a streptavidin - horseradish peroxidase conjugate for 30 min. A solution including the stabilized chromogen was added to each well and incubated for 30 min at room temperature. The reaction was stopped by adding 1 N sulfuric acid. The optical density was measured at 450 nm wavelength using an ELISA reader (Bio Rad). The concentration of sFas in serum samples was determined from the standard curve. All assays were conducted in duplicates, and the mean concentration of sFas was calculated.

Electron Microscopic and Immunoelectron Microscopic Examination of Peripheral Blood Monocytic Cells (PBMNCs) using Agarose Cell Block Technique (Mansy, 2004).

Solidified agarose blocks of separated cells were refixed in buffered 4% glutaraldehyde for 1 hour then postfixed in 2% osmic acid for 1 hour, dehydrated in ascending alcohol, then infiltrated and embedded in epoxy resin. Ultrathin sections were performed using Leica Ultramicrotome (Leica Microsystems GmbH, Ernst-Leitz-Strasse, Austria). The sections were stained with uranyl acetate and lead citrate and examined using Philips Microscopic Electron Microscope 208 S (Eindhoven, The Netherlands). IEM examination was performed on other part of separated cells using rabbit polyclonal anti-Fas antibodies (Maixin-Bio) as above method of Immunohistochemical analysis then processed into agarose cell block and prepared for EM examination as above.

**Statistical analysis**

Statistical evaluation of results was done using SPSS computer program (version 12 windows). Results were expressed as mean ± standard deviation (SD) or number (%). Comparison between the mean values of different parameters in the different groups were performed using one way analysis of variance (ANOVA) with post hoc using least significant difference. Correlation between parameters was performed using Spearman’s rank correlation coefficient ($r$) (Petei and Sabin, 2001). P value < 0.05 was considered significant and < 0.01 was considered highly significant.
Results:

Hepatic Expression of Fas/ FasL antigen
Fas/FasL protein was observed in the membrane ± cytoplasm of hepatocytes with occasional perinuclear staining. In the current study, normal liver specimens showed faint Fas protein expression and no detectable FasL protein expression. Both antigens were significantly increased in the diseased groups (p<0.01) compared to the control specimens (Table I, II and III). In CHC, Fas was detected among infiltrating lymphocytes at the advancing edges of piecemeal necrosis (interface hepatitis). Moreover, FasL protein was expressed dominantly in the infiltrating mononuclear cells in the portal area and hepatic sinusoid. Our data (Table I, II and III) showed a progressive Fas and FasL increase from CHC without cirrhosis to CHC with cirrhosis. Hepatic Fas expression was significantly decreased on comparing HCC to cirrhotic patients p<0.5. On the other hand FasL expression in HCC group showed a non significant difference compared to CHC with cirrhosis.

In CHC, apoptotic Fas and FasL proteins expression was significantly increased with the necroinflammatory activity and the advancement of fibrosis according to the METAVIR scoring systems (table IV and V) (Figures 1 and 2).

Serum level of sFas
Concentrations of studied parameter in CHC, HCC patients and normal controls are shown in Table I, IV, and V. The serum level of sFas in both HCC and cirrhotic patients were significantly higher than those of normal controls and CHC without cirrhosis (P<0.01), but there was no significant difference between cirrhosis and HCC patients.

Correlation analysis between different studied parameters was demonstrated in (table VI).
Table (I): Mean ± SD of the studied parameters in all groups

<table>
<thead>
<tr>
<th></th>
<th>Control (n=10)</th>
<th>CHC without cirrhosis (n=30)</th>
<th>CHC with cirrhosis (n=30)</th>
<th>HCC (n=30)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tissue Fas</strong></td>
<td>1.8 ± 0.8</td>
<td>25.0 ± 5.74&lt;sup&gt;a&lt;/sup&gt;</td>
<td>61.36 ± 4.69&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>27.3±5.6&lt;sup&gt;ac&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Tissue FasL</strong></td>
<td>00 ± 00</td>
<td>33.46 ±11.91&lt;sup&gt;a&lt;/sup&gt;</td>
<td>49.83 ±8.20&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>45.32±6.41&lt;sup&gt;ab&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>sFas pg/ml</strong></td>
<td>165.5 ± 45.6</td>
<td>238.27±135.29&lt;sup&gt;a&lt;/sup&gt;</td>
<td>814.94±362&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>762.18±437&lt;sup&gt;ab&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup>p Statistically significant from control group (p<0.01).
<sup>b</sup>p Statistically significant from CHC without cirrhosis group (p <0.01).
<sup>c</sup>p Statistically significant from cirrhosis group (p <0.01)

Table (II): Tissue Expression of Fas Immunostain in Liver Tissue

<table>
<thead>
<tr>
<th>Histopathologic Diagnosis (n)</th>
<th>Positive Cases</th>
<th>Range %</th>
<th>Intensity%</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No</td>
<td>%</td>
<td>&lt;10%</td>
</tr>
<tr>
<td>Controls (10)</td>
<td>2</td>
<td>20</td>
<td>2</td>
</tr>
<tr>
<td>CHC without cirrhosis (30)</td>
<td>10</td>
<td>33.3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2</td>
</tr>
<tr>
<td>CHC with cirrhosis (30)</td>
<td>16</td>
<td>54.3&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>5</td>
</tr>
<tr>
<td>HCC (30)</td>
<td>13</td>
<td>43.3&lt;sup&gt;abc&lt;/sup&gt;</td>
<td>1</td>
</tr>
</tbody>
</table>

<sup>a</sup>p<0.01 significant difference relative to control group.
<sup>b</sup>p<0.05 significant difference relative to CHC without cirrhosis.
<sup>c</sup>p<0.05 significant difference relative to CHC with cirrhosis.

Table (III): Tissue Expression of FasL Immunostain in Liver Tissue

<table>
<thead>
<tr>
<th>Histopathologic Diagnosis (n)</th>
<th>Positive Cases</th>
<th>Range %</th>
<th>Intensity%</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No</td>
<td>%</td>
<td>&lt;10%</td>
</tr>
<tr>
<td>Controls (10)</td>
<td>0</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>CHC without cirrhosis (30)</td>
<td>13</td>
<td>43.3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>3</td>
</tr>
<tr>
<td>CHC with cirrhosis (30)</td>
<td>17</td>
<td>56.6&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>6</td>
</tr>
<tr>
<td>HCC (30)</td>
<td>16</td>
<td>53.3&lt;sup&gt;ac&lt;/sup&gt;</td>
<td>2</td>
</tr>
</tbody>
</table>

<sup>a</sup>p<0.01 significant difference relative to control group.
<sup>b</sup>p<0.05 significant difference relative to CHC without cirrhosis.
<sup>c</sup>p<0.05 significant difference relative to CHC with cirrhosis.
Table (IV): Mean ± SD of the studied parameters according to METAVIR activity scoring system in CHC with or without cirrhosis groups.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>A1 (n=28)</th>
<th>A2 (n=18)</th>
<th>A3(n=14)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tissue Fas</td>
<td>23.57 ± 5.75</td>
<td>27.500 ± 3.54</td>
<td>43.00 ± 4.43&lt;sup&gt;ab&lt;/sup&gt;</td>
</tr>
<tr>
<td>Tissue FasL</td>
<td>17.14 ± 4.23</td>
<td>20.00 ± 7.32</td>
<td>45.40 ± 6.42&lt;sup&gt;ab&lt;/sup&gt;</td>
</tr>
<tr>
<td>s Fas pg/ml</td>
<td>210.4 ± 23.2</td>
<td>395.8 ± 41.4&lt;sup&gt;a&lt;/sup&gt;</td>
<td>447.5 ± 51.7&lt;sup&gt;ab&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup>p Statistically significant from A1 group (<i>p</i> < 0.01).
<sup>b</sup>p Statistically significant from A2 group (<i>p</i> < 0.01).

Table (V): Mean ± SD of the studied parameters according to METAVIR fibrosis scoring system in CHC with or without cirrhosis groups.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>F1 (n=24)</th>
<th>F2 (n=15)</th>
<th>F3 (n=14)</th>
<th>F4 (n=7)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tissue Fas</td>
<td>17.40 ± 6.21</td>
<td>19.759 ± 9.76</td>
<td>23.04 ± 2.08&lt;sup&gt;a&lt;/sup&gt;</td>
<td>33.28 ± 5.16&lt;sup&gt;abc&lt;/sup&gt;</td>
</tr>
<tr>
<td>Tissue FasL</td>
<td>15.160 ± 5.02</td>
<td>18.75 ± 1.30</td>
<td>21.41 ± 2.28&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>28.42 ± 6.06&lt;sup&gt;ab&lt;/sup&gt;</td>
</tr>
<tr>
<td>s Fas pg/ml</td>
<td>200.4 ± 47.1</td>
<td>250.3 ± 33.6</td>
<td>260.4 ± 54.7&lt;sup&gt;a&lt;/sup&gt;</td>
<td>340.3 ± 65.4&lt;sup&gt;abc&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup>p Statistically significant from F1 group (<i>p</i> < 0.01).
<sup>b</sup>p Statistically significant from F2 group (<i>p</i> < 0.01).
<sup>c</sup>p Statistically significant from F3 group (<i>p</i> < 0.01).

Table (VI): Correlation of tissue expression of different parameters in studied groups

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Correlation coefficient (r)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tissue Fas versus Tissue FasL</td>
<td>0.753</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Tissue Fas versus sFas pg/ml</td>
<td>-0.321</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Tissue FasL versus sFas pg/ml</td>
<td>0.682</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>
Figure 1: Immunostain for Fas monoclonal antibody, A) a case of CHC without cirrhosis, A1F1 showing mild expression of Fas as membranous ± cytoplasmic stain in the hepatocytes and in lymphocytes at the periportal area (IHC, DAB, X 200). B) a case of CHC with cirrhosis, A2F2, showing moderate expression of Fas as membranous ± cytoplasmic stain in the hepatocytes and in lymphocytes at the periportal area (IHC, DAB, X 200). C) a case of CHC with cirrhosis, A2F3, showing cirrhotic nodule with moderate to marked expression of Fas as membranous ± cytoplasmic stain in the hepatocytes and in lymphocytes at the periportal area (IHC, DAB, X 100). D) a case of moderately differentiated HCC showing mildly expressed Fas in the cytoplasm of hepatocytes (IHC, DAB, X400)
**Figure 2:** Immunostain for Fas ligand monoclonal antibody, A) a case of CHC without cirrhosis A1F1 showing mild expression of Fas ligand as cytoplasmic stain in the hepatocytes (IHC, DAB, X200), B) a case of CHC with cirrhosis A2F2 showing moderate expression of Fas ligand as cytoplasmic stain in the hepatocytes (IHC, DAB, X200), C) a case of CHC with cirrhosis showing cirrhotic nodule with moderate expression of Fas ligand as cytoplasmic stain in the hepatocytes. (IHC, DAB, X100), D) a case of moderately differentiated HCC showing moderate expressed Fas ligand in the cytoplasm of hepatocytes (IHC, DAB, X200).

**Discussion**

Apoptosis is central for the control and elimination of viral infections. In chronic HCV infection, enhanced hepatocyte apoptosis and up-regulation of the death inducing ligands occur.
Nevertheless, HCV infection persists in the majority of patients (Bantel and Schulze, 2003). The impact of apoptosis in chronic HCV infection is not well understood. It may be harmful by triggering liver fibrosis, or essential in interferon induced HCV elimination (Fisher et al., 2007). In addition, escape from the immune surveillance may play an important role in tumor outgrowth and metastasis.

The Fas receptor/ligand system including soluble forms is the most important apoptotic initiator in the liver (Pelli et al., 2007). Dysregulation of this pathway may contribute to abnormal cell proliferation and cell death (Kornmann et al, 2000) and is regarded as one of the mechanisms preventing the immune system from rejecting the tumor cells (Nagao et al, 1999). In this study the immunohistochemical expression of Fas and FasL was determined using specific monoclonal antibodies. In normal liver, Fas was faintly expressed on cytoplasm and membranes of hepatocytes, while FasL was negative. This result was consistent with those of Roskamset et al. (2000) and Leithauser et al. (1993). Data also showed increase expression of Fas receptor and ligand in hepatocytes in liver specimens from CHC patients with and without cirrhosis as compared with controls. Hepatic Fas expression was found to be elevated in chronic hepatitis B (Mochizuki et al, 1996), chronic hepatitis C (Hiramatsu et al., 1994) and (El Bassiouny et al., 2008) and acute liver failure (Galle et al, 1995). Moreover, a progressive Fas and FasL increase from CHC without cirrhosis to CHC with cirrhosis was also observed (Bortolami et al., 2008). Our results suggest that "suicide" and "fratricide" mechanisms proposed by Galle et al. (1995) in the study of alcoholic liver cirrhosis may also work in liver cirrhosis after viral hepatitis C and may explain the mechanism by which apoptosis might be involved in the pathogenesis of liver cirrhosis. "Fratricide", induced by ligation of Fas receptor and FasL expressed on the surface of adjacent cells while "suicide", induced by binding of FasL expressed by hepatocytes to Fas on the surface of themselves.

According to METAVIR activity score system, the up regulation of hepatic Fas expression demonstrated in our study in CHC patients was in accordance with the severity of liver inflammation. Similar results were obtained by Hayashi and Mita, 1997. The histological activity index (HAI) revealed more expression of Fas antigen in liver tissues with active inflammation than in those without active inflammation (El Bassiouny et al., 2006). When HCV-specific T-cells migrate into hepatocytes and recognize the viral antigen via the T-cell receptor, they become activated and express FasL that can transduce the apoptotic death signal to
Fas-bearing hepatocytes (Hayashi and Mita, 1997) and (Galle et al, 1995). This was proved in our study by the prominent expression of FasL protein in the infiltrating mononuclear cells in the portal area and hepatic sinusoid. Thus, the Fas system plays an important role in liver cell injury by HCV infection. Our results also demonstrate that the expression of Fas and FasL increased in the course of liver fibrosis. Several studies have demonstrated increased expression of Fas and FasL in the course of liver fibrosis, which is the most serious consequence of chronic liver injury (El Bassiouny et al, 2008), (Zhang et al, 2006) and (Akazawa and Gores, 2007). Experimentally, the upregulation of Fas expression occurs on stimulation with interferon-gamma released from T-cells (Kawamura et al, 2000). Hepatic fibrogenesis accompanied by hepatocellular necrosis and inflammation was also suggested to be caused by cytokines and transforming growth factor-beta-1 released by Kupfer cells and infiltrating T-lymphocytes (El Bassiouny et al, 2008).

Because hepatic fibrosis is associated with a high incidence of HCC, it was speculated that Fas expression may be involved in the incidence of HCC (Hirashima et al, 2002) and (Kamegaya et al, 2005). In HCC liver biopsies, FasL showed cytoplasmic positivity in hepatocytes in areas of interface hepatitis. Strong expression of Fas as well as FasL in the hepatocytes immediately adjacent to HCC was a constant finding. Within the HCC biopsies, FasL expression was variable, but present only in a minority of cells. Fas varied from a diffuse honeycomb pattern to focal positivity in occasional cells.

In recent years, there is accumulating evidence showing that sFas plays an important role in modulation of apoptosis (Hiramatsu et al., 1994). sFas was capable of inhibiting hepatic apoptosis by binding to FasL or anti-Fas anti-bodies in competition with membrane-bound Fas. sFas protein, composed of the extra cellular region of Fas receptor and Fc sequence of human IgG, inhibited the activity of cytotoxic T-lymphocytes in a dose-dependent manner (Peng et al, 2001). Midis et al.( 1996) reported that patients with non-haematopoietic malignancies exhibit elevated sFas levels compared to normal controls and that sFas can be synthesized and released in the culture supernatants of human solid tumor explants. They also found that the relative elevation of sFas levels in non-haematopoietic cancer patients might be in consistence with both disease stage and tumor burden. Many researchers reported that serum sFas levels in patients with HCC were significantly higher than those in healthy adults (El Bassiouny et al, 2008) and (Peng et al, 2001). Judo et al, 1998 also reported that sFas level was related with the number of tumor nodules,
Early Detection of Hepatocellular Carcinoma on top of Liver Cirrhosis

but not with its size of the solitary nodule. In patients with solitary HCC nodule, serum sFas levels fell rapidly after surgical resection, and went undetectable in one week. This evidence suggested that sFas was generated by tumor cells or at least tumor related. sFas mediated a prereceptorial resistance of Fas-expressing hepatocytes by antagonizing FasL killing of infiltrating CTLs. Fas-bearing tumor cells thus were saved by sFas from the fate of apoptosis and escape the immune surveillance. Our data revealed significantly higher serum sFas levels in HCC patients than those in healthy adults, but shown no significant difference between the levels in HCC and liver cirrhosis patients. This phenomenon may be due to relatively high expression of FasL in HCC cells, and sFas cleaved by metalloproteinases from the transmembrane domain might be capable of binding to sFas, thus accuracy of the measurement was influenced. A linear correspondence between liver tissue expression and serum levels of sFas was also detected.

In Conclusion, apoptosis and the Fas system were significantly involved in the process of liver cirrhosis converting into hepatocellular carcinoma. Down-regulation of Fas expression, up regulation of FasL expression in hepatocytes and elevation of serum sFas level were important in tumor evasion from immune surveillance and in hepatic carcinogenesis.

Therefore warranted and draw the attention to the use of these components of the Fas system as an attractive target for anticancer therapy. In addition, the linear correspondence between liver tissue expression of Fas and its serum levels suggest that they could be considered as a predictive marker for tumorogenesis in HCC.

References


Bortolami M, Kotsafti A, Cardin R and Farinati F (2008): Fas / FasL system, IL-1beta expression and apoptosis in chronic


Early Detection of Hepatocellular Carcinoma on top of Liver Cirrhosis.

The diagnosis of hepatocellular carcinoma in cases of liver cirrhosis: role of future and its derivatives

A. Hameed, M. Zeher, A. Mahmoud, S. Aley, K. Hessany, A. Halmi, A. Ans

- Department of Pathology, Theodore Research Institute, Giza, Arab Republic of Egypt
- Department of Blood Diseases, Theodore Research Institute, Giza, Arab Republic of Egypt
- Medical Institute and Dental College, Malayan Institute of Research and Chemical Pharmacology, Cairo, Arab Republic of Egypt
- Department of General Surgery, Faculty of Medicine, Cairo University, Arab Republic of Egypt
- Department of Blood and Pathology, Theodore Research Institute, Giza, Arab Republic of Egypt
- Department of Liver and GI Diseases, Theodore Research Institute, Giza, Arab Republic of Egypt

Hepatitis B virus-related liver cirrhosis may develop into hepatocellular carcinoma due to long-term hepatitis B virus infection and continuous efforts of the immune system to eliminate the virus and the infected liver cells, which leads to liver fibrosis and chromosomal alteration in liver cells that develop into liver cancer. From the regulated substances of future and its derivatives (future-α and future-β) and their crosslinking compound, these substances can recognize and eliminate cancerous cells. However, cancer cells acquire resistance to future and its functions and avoid destruction.

Purpose of the study:

To measure the levels of future and its derivatives (future-β) in liver cancer cells and their derivatives (future-α) in blood and future-α in white blood cells in an attempt to determine their roles in the development of cancer and then use them for early detection of liver cancer and as a target for chemotherapy.

Methodology:
The study included 100 cases, from cases treated at Theodore Research Institute and the National Institute in the Arab Republic of Egypt. We collected blood samples from 90 cases of hepatitis B virus-induced liver cirrhosis, of which 30 cases had no liver fibrosis, 30 cases had liver fibrosis, and 30 cases had liver cancer. We collected 10 samples from healthy livers for comparison. We measured future and future-β in liver tissues using immunohistochemistry and future-α in blood and future-α using electron microscopy on white blood cells.

Results:

We found a significant increase in the levels of future in blood samples of liver fibrosis cases and liver cancer cases compared to healthy cases and hepatitis B without fibrosis. A significant increase in the levels of future and future-β in liver cells was observed in all groups compared to the healthy group. These levels increased with hepatitis B without fibrosis and then increased gradually with the increase of liver fibrosis and then decreased with the appearance of liver cancer. There was a negative correlation between future-α in blood and future-β in liver samples, but it was not significant. Future-α in blood increased with the increase in liver cell death.

Conclusion:

Future regulatory system has a regulatory role in the development of liver cancer. A decrease in the expression of future, an increase in the expression of its crosslinking compound in liver cells, and an increase in the expression of future-α in blood lead to the development of liver cancer.

Conclusions:

A significant correlation was found between the presence of liver cancer and the presence of future derivatives, and this correlation increased significantly with the increase in liver fibrosis. This indicates that future derivatives can be used as a target for chemotherapy in liver cancer.

References:

Early Detection of Hepatocellular Carcinoma on top of Liver Cirrhosis....